Results 21 to 30 of about 100,944 (279)

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Pediatric Rheumatology Online Journal, 2018
Tocilizumab, an anti-interleukin-6 (IL-6) agent, is indicated as a treatment for several autoimmune or inflammatory diseases, including rheumatoid arthritis and juvenile idiopathic arthritis (JIA). IL-6 plays roles in both immune system dysregulation and
Ju-Yang Jung, Moon-Young Kim, Chang-Hee Suh, Hyoun-Ah Kim   +3 more
doaj   +1 more source

First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia

Frontiers in Medicine, 2020
Introduction/objectives: An interleukin-6 inhibition strategy could be effective in selected COVID-19 patients. The objective is to present our experience of tocilizumab use in patients with severe COVID-19.Methods: Observational retrospective cohort ...
Omar Valenzuela, Omar Valenzuela, Sebastián Ibáñez, Sebastián Ibáñez, M. Cecilia Poli, M. Cecilia Poli, M. Cecilia Poli, Patricia Roessler, Patricia Roessler, Mabel Aylwin, Mabel Aylwin, Gigia Roizen, Gigia Roizen, Mirentxu Iruretagoyena, Mirentxu Iruretagoyena, Vivianne Agar, Vivianne Agar, Javiera Donoso, Javiera Donoso, Margarita Fierro, Margarita Fierro, José Montes, José Montes   +22 more
doaj   +1 more source

Tocilizumab Is Associated with Increased Risk of Fungal Infections among Critically Ill Patients with COVID-19 and Acute Renal Failure: An Observational Cohort Study

Life, 2023
Research Question: Does treatment with tocilizumab increase the risk of a fungal infection in critically ill patients with coronavirus-19? Background: Numerous therapies have been evaluated as possible treatments for coronavirus-2019 caused by severe ...
Barrett J. Burger, Sarenthia M. Epps, Victor M. Cardenas, Rajani Jagana, Nikhil K. Meena, William T. Atchley   +5 more
doaj   +1 more source

Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritis

Качественная клиническая практика, 2020
Rationale. Rheumatoid arthritis (RA) and systemic juvenile arthritis (sJA) are the most frequent rheumatic diseases in adults and adolescents, consequently. Biologics disease modifying antirheumatic drugs (bDMARDs) are eff ective in treatment of RA and s
A. S. Kolbin, A. A. Kurylev, S. A. Mishinova, Yu. E. Balykina, M. A. Proskurin   +4 more
doaj   +1 more source

Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an in vitro Model of Inflammation

Frontiers in Genetics, 2021
COVID-19 has posed a significant threat to global health. Early data has revealed that IL-6, a key regulatory cytokine, plays an important role in the cytokine storm of COVID-19.
Arya Zarinsefat, George Hartoularos, Dmitry Rychkov, Priyanka Rashmi, Sindhu Chandran, Flavio Vincenti, Chun J. Yee, Minnie M. Sarwal   +7 more
doaj   +1 more source

Rheumatoid arthritis [PDF]

, 2016
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel, McInnes, Iain B., Smolen, Josef S.   +2 more
core   +1 more source

Avaliação à medida no Segundo HAREM [PDF]

, 2008
Objectives This study compared the efficacy and safety of subcutaneous (SC) versus intravenous (IV) formulations of tocilizumab in patients with rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs (DMARD).
Bao, Min, Burmester, Gerd R., Cantagrel, Alain, Feldman, Daniel, Hall, Stephen, Leszczynski, Piotr, Lu, Peng, Ludivico, Charles, Mysler, Eduardo F., Rangaraj, Madura J., Roane, Georgia, Rowell, Lucy, Rubbert-Roth, Andrea   +12 more
core   +2 more sources

Successful Use of Tocilizumab in a Patient with Coexisting Rheumatoid Arthritis and Ulcerative Colitis

Case Reports in Immunology, 2016
Tocilizumab is an interleukin-6 receptor inhibitor licensed for moderate to severe rheumatoid arthritis (RA). We report a case of Tocilizumab monotherapy for severe active RA in a patient with coexisting ulcerative colitis (UC).
Matthew Chak Hin Szeto, Metin Devrim Yalçın, Abdul Khan, Andrzej Piotrowicz   +3 more
doaj   +1 more source

Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment

Scientific Reports, 2022
We compared the efficacy of tocilizumab and etanercept in inhibiting radiographic progression of joint destruction in rheumatoid arthritis. Overall, 187 patients treated with etanercept or tocilizumab were selected.
Shinya Hayashi, Tsukasa Matsubara, Toshihisa Maeda, Koji Fukuda, Keiko Funahashi, Marowa Hashimoto, Ken Tsumiyama, Tomoyuki Kamenaga, Yoshinori Takashima, Tomoyuki Matsumoto, Shotaro Tachibana, Ryosuke Kuroda   +11 more
doaj   +1 more source

Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients

International Journal of Infectious Diseases, 2021
Objectives: The purpose of this study is to evaluate clinical outcomes in patients with critical COVID-19 pneumonia requiring invasive mechanical ventilation who were treated with tocilizumab Design: Single-center retrospective cohort study Setting ...
Matthew J. Fisher, Luis A. Marcos Raymundo, Melinda Monteforte, Erin M. Taub, Roderick Go   +4 more
doaj   +1 more source